Skip to content
An Initiative of AVAC
Search

Resource Library

The PrEPWatch Resource Database offers a wide range of material on the status of PrEP as an option for biomedical HIV prevention around the world. Search this database to find step-by-step guidance for rolling out PrEP, summaries of the research to date on safety, efficacy and implementation, tools to assist planning and roll out, country updates on PrEP policy and access, and lessons learned from those efforts.

Filter By
Multiple filters can be used at once

Showing results 261 - 270 of 400

Selected Filters:
31 August 2022

Coordinating Implementation Science for CAB for PrEP: Focus on Delivery Models

This second meeting of the BioPIC implementation science series focused on how cabotegravir (CAB) for PrEP can be integrated into existing community, pharmacy and facility-based delivery for HIV prevention.

Research

Document
30 August 2022

How Gender Norms and ‘Good Girl’ Notions Prevent Adolescent Girls and Young Women from Engaging with PrEP: Qualitative insights from Zimbabwe

This article from BMC Women’s Health explores the role of gender norms in shaping adolescent girls and young women’s (AGYW) engagement with PrEP in Zimbabwe.

Monitoring & Evaluation, Research

External Link
30 August 2022

More than Just Oral PrEP: Exploring interest in rectal douche, dissolvable implant, removable implant and injection HIV prevention approaches among racially diverse men who have sex with men in the Northeast Corridor

This exploratory and cross-sectional study investigated interest in four biomedical prevention tools—rectal douche, dissolvable implant, removable implant and injection—among a racially diverse sample of men who have sex with men from the Northeast Corridor region between Philadelphia and Trenton.

Research

External Link
19 August 2022

Implementation Science Questions for CAB for PrEP

This document outlines the key evidence gaps around cabotegravir (CAB) for PrEP that should be addressed when designing implementation research.

Research

Document
16 August 2022

Background Resources on Cabotegravir for PrEP

This document, produced by the MOSAIC consortium, provides a list of key resources on research and evidence for cabotegravir (CAB) for PrEP.

Research

Document
15 August 2022

By women, for women: A story of rings, research and resolve

This dynamic photo story from the International Partnership for Microbicides explains how the dapivirine vaginal ring was conceived, and the journey it has taken to becoming an HIV prevention choice for women.

Community/Advocacy, Research

External Link
12 August 2022

HIV Prevention Research and Development Database

The HIV Prevention Research & Development Database is a comprehensive source of information on biomedical HIV prevention clinical trials that are planned, ongoing or completed. The database allows users to view clinical trials around the world, gaining an understanding of the many developments currently being made in the field of HIV prevention research.

Research

External Link
12 August 2022

Plan 4 Ring Toolkit: Implementation Study Protocol Template

This template is designed for policymakers and government technical specialists to apply uniform objectives, study design features, and measures across pilot implementation and other operations research studies for introduction of the dapivirine ring. This tool is part of the Plan 4 Ring toolkit, a suite of resources and tools designed to support national planning for…

Research

Document
8 August 2022

Long-Acting Injectable Cabotegravir: Implementation science needed to advance this additional HIV prevention choice

In this article, the authors outline priority areas for implementation research needed to inform the effective scale-up of cabotegravir for PrEP.

Research

External Link
8 August 2022

Sustained Efficacy of Long-Acting Cabotegravir for PrEP Among Cisgender Women

This press release provides an overview of the new findings from HPTN 084, a trial of the HIV Prevention Trials Network studying injectable cabotegravir for PrEP among cisgender women. The updated results show reductions in HIV incidence were sustained in the 12 months following unblinding and were presented at the AIDS 2022 conference in Montreal.

Research

External Link